News articles about Merus Labs International (NASDAQ:MSLI) (TSE:MSL) have been trending very positive recently, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merus Labs International earned a media sentiment score of 0.65 on Accern’s scale. Accern also assigned news stories about the company an impact score of 84 out of 100, meaning that recent press coverage is very likely to have an effect on the company’s share price in the next few days.
Several equities research analysts have commented on the company. Zacks Investment Research upgraded Merus Labs International from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 18th. Canaccord Genuity lowered Merus Labs International to a “hold” rating and set a $1.65 price objective on the stock. in a research report on Thursday, May 11th. Seven investment analysts have rated the stock with a hold rating, The company has an average rating of “Hold” and an average target price of $1.35.
Shares of Merus Labs International (NASDAQ MSLI) remained flat at $1.30 on Friday. 9,409 shares of the company traded hands. The firm’s 50 day moving average is $1.20 and its 200 day moving average is $0.94. Merus Labs International has a 12-month low of $0.70 and a 12-month high of $1.33. The firm’s market cap is $152.56 million.
COPYRIGHT VIOLATION NOTICE: This report was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/07/29/merus-labs-international-nasdaqmsli-receiving-very-positive-press-coverage-report-finds-updated-updated-updated.html.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.